Multiple Sclerosis: KOL Insight 2016

Transcription

1 Multiple Sclerosis: KOL Insight 2016

2 Multiple Sclerosis: KOL Insight 2016 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0) or reportstore@bioportfolio.com 2

3 Multiple Sclerosis: KOL Insight 2016 Big changes ahead as Ocrevus nears approval. How will it affect your brand? Oral therapies are replacing interferons as the mainstay Multiple Sclerosis (MS) treatment, but the big news is the pending approval of Roche/Biogen s Ocrevus, a powerful monoclonal antibody for relapsing and progressive MS patients that promises to upend the treatment algorithm. Get the details in KOL Insight: Multiple Sclerosis. Based on interviews with 12 US and European KOLs, the report gives you their candid thoughts about 12 marketed therapies and 11 more in the pipeline. You ll learn what the future holds for interferons, how oral agents are faring, and how pipeline treatments from sphingosine modulators, to monoclonal antibodies, pharmaceutical-grade biotin, and other novel mechanisms of action are likely to compete with established therapies. Ocrevus has the potential to really change the landscape and, from a patient perspective, sounds pretty easy. EU Key Opinion Leader Take a tour of the report now: The table of contents > The key questions answered > The key KOL quotes > See the 23 therapies covered > Find out who the 12 EU & US KOLs are > Review an extract from the report - 1 drug profile > Sample of therapies covered: Zinbryta (daclizumab; Biogen/AbbVie) Ocrevus (ocrelizumab; Roche/Biogen) ofatumumab (Novartis/Genmab) Biotin (MD 1003; MedDay/Medical Need) siponimod (BAF 312; Novartis) Plus 18 more download the full list now > Sample of KOLS interviewed 3

4 Prof Shiv Saidha, MD, MBBCh. Associate Professor of Neurology, Johns Hopkins Medicine, Baltimore, Maryland, USA. Prof Bianca Weinstock-Guttman, MD. Professor of Neurology and Director of the Jacobs Multiple Sclerosis Center for Treatment and Research, University at Buffalo, New York, USA. Prof Mark Freedman, MD. Professor of Medicine in the field of Neurology, University of Ottawa and Director of the Multiple Sclerosis Research Unit, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada. Prof Gilles Defer, MD. Head of the Department of Neurology, University Hospital of Caen, France. Prof Per Soelberg Sørensen, MD. Professor of Neurology, University of Copenhagen and Director of the Danish Multiple Sclerosis Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Plus 7 more download the full list now > Top Takeaways Once approved, Ocrevus will revolutionise MS treatment: Not just the relapsing remitting form but progressive forms as well, KOLs say. What are the most likely indications for Ocrevus, and will it see first-line usage? Interferons in decline: More neurologists are prescribing other agents instead, a trend KOLs expect to continue even as interferon use persists in specific indications. What s behind the drop-off in interferon use, and in which patients will doctors continue to prescribe them? Next-generation sphingosine modulators may threaten Gilenya: What will these pipeline agents need to show to gain widespread adoption? Copaxone still going strong: Considered the safest MS therapy, Copaxone continues to appeal to risk-averse patients. Has the introduction of generic glatiramer acetate had an impact on Copaxone prescribing? Future unclear for Zinbryta: Launched into a crowded marked, Biogen/AbbVie s Zinbryta may struggle to find a niche. What advantages and drawbacks do KOLs say will determine the drug s short-term prospects? Which potential competitor looms longer-term? Tecfidera use has plateaued: Safety concerns have made neurologists more cautious about using Tecfidera. Do KOLs expect prescriptions to decline or stay the same? Which Tecfidera competitor is benefitting most from the uncertainty? KOLs excited about MD 1003: Intrigued by the potential of pharmaceutical-grade biotin, KOLs are calling for larger trials. What are their most pressing questions and concerns? Where do they see MD 1003 entering the treatment algorithm? Novel MoAs hold promise: Despite disappointing study results, KOLs are keeping a close eye on Biogen s anti- LINGO-1 mab, opicinumab. What has them interested, and what do they suggest as next steps for evaluating the drug? Money Back Guarantee At FirstWord, we stand behind our reports. If you're not completely satisfied, we ll refund your money. Guaranteed. About FirstWord 4

5 FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence. FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company s success. FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today. Additional Details Publisher : FirstWord Pharma Reference : Number of Pages : 0 Report Format : PDF Publisher Information : 5

6 Table Of Contents for Multiple Sclerosis: KOL Insight 2016 [Report Updated: ] 1.Executive summary 2.Research Objectives 3.Research Focus 4.Marketed Therapies 4.1 Overview 4.2 Interferon beta 4.3 Copaxone (glatiramer acetate; Teva) 4.4 Tecfidera (dimethyl fumarate; Biogen) 4.5 Aubagio (teriflunomide; Sanofi) 4.6 Gilenya (fingolimod; Novartis) 4.7 Tysabri (natalizumab; Biogen) 4.8 Lemtrada (alemtuzumab; Sanofi) 4.9 Zinbryta (daclizumab; Biogen/AbbVie) 5. Pipeline Drugs 5.1 Overview 5.2 Ocrevus (ocrelizumab; Roche/Biogen) 5.3 Ofatumumab (Novartis/Genmab) 5.4 Cladribine (Merck Group) 5.5 Nerventra (laquinimod; Active Biotech/Teva) 5.7 Sphingosine modulators 5.8 ALKS 8700 (Alkermes) 5.9 Biotin (MD1003; MedDay/Medical Need) 6.Earlier-stage developments in MS 7.Current and future treatment algorithm 8.Appendix 8.1KOL biographies 6

7 How to Buy... Multiple Sclerosis: KOL Insight 2016 [Report Updated: ] Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0) We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $7900 Single User Price $20500 Global License Price Payment Options: (please tick one) Online Credit Card (we will you the invoice with a payment link) Direct Wire Transfer (we will you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0) We will be delighted to give you our personal attention. 7